"Because we are in a health care setting, masks are still required in all facilities. Thank you for helping keep our patients and staff safe."

During the past decade, University of Colorado Cancer Center - Anschutz Cancer Pavilion conducted 71 clinical trials. In the 10-year time frame, 71 clinical trials started and 68 clinical trials were completed, i.e. on average, 95.8% percent of trials that started reached the finish line to date. In the past 5 years, 32 clinical trials started and 32 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Colorado Cancer Center - Anschutz Cancer Pavilion" #1 sponsor was "National Cancer Institute (NCI)" with 22 trials, followed by "Pfizer" with 22 trials sponsored, "Gynecologic Oncology Group" with 10 trials sponsored, "Hoffmann-La Roche" with 10 trials sponsored and "SWOG Cancer Research Network" with 10 trials sponsored. Other sponsors include 70 different institutions and companies that sponsored additional 59 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Colorado Cancer Center - Anschutz Cancer Pavilion" #1 collaborator was "National Cancer Institute (NCI)" with 31 trials as a collaborator, "NRG Oncology" with 14 trials as a collaborator, "Astellas Pharma Inc" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator and "AstraZeneca" with 2 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "University of Colorado Cancer Center - Anschutz Cancer Pavilion" are "Melanoma" (6 trials), "Prostate Cancer" (6 trials), "Breast Cancer" (5 trials), "Ovarian Clear Cell Cystadenocarcinoma" (5 trials) and "Recurrent Uterine Corpus Carcinoma" (5 trials). Many other conditions were trialed in "University of Colorado Cancer Center - Anschutz Cancer Pavilion" in a lesser frequency.

Most popular intervention types in "University of Colorado Cancer Center - Anschutz Cancer Pavilion" are "Drug" (122 trials), "Other" (38 trials), "Biological" (28 trials), "Procedure" (11 trials) and "Radiation" (7 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (21 trials), "Placebo" (9 trials), "Bevacizumab" (7 trials), "Atezolizumab" (6 trials) and "Carboplatin" (6 trials). Other intervention names were less common.

The vast majority of trials in "University of Colorado Cancer Center - Anschutz Cancer Pavilion" are 106 trials for "All" genders, 29 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are NaN active trials in "University of Colorado Cancer Center - Anschutz Cancer Pavilion". undefined are not yet recruiting, 21 are recruiting, 27 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 78 completed trials in University of Colorado Cancer Center - Anschutz Cancer Pavilion, 1 suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in University of Colorado Cancer Center - Anschutz Cancer Pavilion, 48 "Phase 1" clinical trials were conducted, 67 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".